Provided by Tiger Trade Technology Pte. Ltd.

Generate Biomedicines

17.72
+1.609.93%
Post-market: 17.960.2400+1.35%18:30 EDT
Volume:2.50M
Turnover:43.12M
Market Cap:2.27B
PE:-5.41
High:17.99
Open:16.67
Low:16.03
Close:16.12
52wk High:18.18
52wk Low:11.00
Shares:128.19M
Float Shares:60.29M
Volume Ratio:2.78
T/O Rate:4.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2762
EPS(LYR):-4.9816
ROE:-81.72%
ROA:-34.63%
PB:4.98
PE(LYR):-3.56

Loading ...

Company Profile

Company Name:
Generate Biomedicines
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
312
Office Location:
101 South Street,Suite 900,Somerville,Massachusetts,United States
Zip Code:
02143
Fax:
- -
Introduction:
Generate Biomedicines, Inc. was incorporated in August 2018 under Delaware law. As a clinical-stage generative biology company, it pioneered an AI-driven biotechnology platform called the Generate Platform, which combines computational models with scalable biological hardware to design and develop novel therapeutic proteins. Its most advanced candidate, GB-0895, is a computationally engineered anti-TSLP monoclonal antibody currently in a pivotal Phase 3 trial for severe asthma. The platform's capabilities have been further demonstrated by advancing two additional oncology candidates into Phase 1 trials by 2026.

Directors

Name
Position
Michael Nally
Chief Executive Officer and Director
Noubar B. Afeyan
Chairperson of the Board
Frances H. Arnold
Director
Jane Mendillo
Director
Marsha H. Fanucci
Director
Nancy A. Simonian
Director
Paul Parker
Director
Rupert Vessey
Director
Stéphane Bancel
Director

Shareholders

Name
Position
Michael Nally
Chief Executive Officer and Director
Jason Silvers
Chief Financial Officer and President
Aarif Khakoo
Chief Scientific Officer
Beth Grous
Chief People Officer
Gevorg Grigoryan
Chief Technology Officer and Co-Founder
Laurie Lee
Chief Medical Officer
Sean Martin
Chief Legal Officer and General Counsel